Theravance Biopharma, Inc. | Uncategorized | Business Contracts

Offer Letter with Aziz Sawaf dated June 16, 2014 (Filed With SEC on May 10, 2023)

Offer Letter with Brett Grimaud dated May 12, 2014 (Filed With SEC on May 10, 2023)

Audited financial statements of Theravance Respiratory Company, LLC for the year ended December 31, 2021 (Filed With SEC on March 1, 2023)

Master Consent, dated as of July 13, 2022, by and among Glaxo Group Limited, Theravance Biopharma, Inc. and Royalty Pharma Investments 2019 ICAV (Filed With SEC on July 14, 2022)

Audited financial statements of Theravance Respiratory Company, LLC for the year ended December 31, 2021 (Filed With SEC on February 28, 2022)

Offer Letter with Richard Graham August 12, 2015 (Filed With SEC on November 9, 2020)

First Amendment of Registration Rights Agreement with Glaxo Group Limited (Filed With SEC on May 8, 2020)

Brett K. Haumann Theravance Biopharma UK Ltd. Contract of Employment (Filed With SEC on May 8, 2020)

Brett K. Haumann Transfer to Theravance Biopharma UK Ltd. Memo (Filed With SEC on May 8, 2020)

Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 27, 2020)

Offer Letter with Andrew Hindman dated May 30, 2019 (Filed With SEC on August 5, 2019)

Form of Note Purchase Agreement, dated November 30, 2018 (Filed With SEC on December 3, 2018)

Asset Purchase Agreement, dated as of November 1, 2018, by and among Cumberland Pharmaceuticals Inc. on the one hand, and Theravance Biopharma Ireland Limited and Theravance... (Filed With SEC on November 16, 2018)

Amendments to Lease for 901 Gateway Boulevard between Theravance Biopharma US, Inc. and ARE-901/951 Gateway Boulevard, LLC (Filed With SEC on August 2, 2018)

Memorandum to Brett K. Haumann regarding Transfer to Theravance Biopharma US, Inc., executed April 5, 2018 (Filed With SEC on August 2, 2018)

Amendments to Lease for 951 Gateway Boulevard between Theravance Biopharma US, Inc. and ARE-901/951 Gateway Boulevard, LLC (Filed With SEC on August 2, 2018)

Amendment and Termination of Rights Agreement, dated as of May 1, 2018, between the Company and Computershare Inc (Filed With SEC on May 1, 2018)

Form of Notice of Performance Restricted Share Unit Award and Restricted Share Unit Agreement under the Companys Performance Incentive Plan (Filed With SEC on November 8, 2017)

Form of Notice of Option Grant and Option Agreement under the Companys Performance Incentive Plan (Filed With SEC on November 8, 2017)

Offer Letter with Shehnaaz Suliman dated May 31, 2017 (Filed With SEC on November 8, 2017)

THIRD AMENDMENT TO TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT between HOSPIRA WORLDWIDE, INC. and THERAVANCE BIOPHARMA IRELAND LIMITED (Filed With SEC on November 9, 2016)

FIRST AMENDMENT TO TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT BETWEEN HOSPIRA WORLDWIDE, INC. and THERAVANCE, INC. (Filed With SEC on November 9, 2016)

SECOND AMENDMENT TO TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT between BETWEEN HOSPIRA WORLDWIDE, INC. and THERAVANCE BIOPHARMA ANTIBIOTICS, INC. (Filed With SEC on November 9, 2016)

FOURTH AMENDMENT TO TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT between PFIZER, INC. and THERAVANCE BIOPHARMA IRELAND LIMITED (Filed With SEC on November 9, 2016)

THERAVANCE BIOPHARMA, INC. (a Cayman Islands exempted company) 3,850,000 Ordinary Shares UNDERWRITING AGREEMENT (Filed With SEC on November 2, 2016)

THERAVANCE BIOPHARMA, INC. (a Cayman Islands exempted company) $200,000,000 3.250% Convertible Senior Notes due 2023 UNDERWRITING AGREEMENT (Filed With SEC on November 2, 2016)

THERAVANCE BIOPHARMA, INC. as Issuer and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee Trustee Indenture Dated as of November 2, 2016 (Filed With SEC on November 2, 2016)

THERAVANCE BIOPHARMA, INC. 3.25% CONVERTIBLE SENIOR NOTES DUE 2023 FIRST SUPPLEMENTAL INDENTURE DATED AS OF NOVEMBER 2, 2016 WELLS FARGO BANK, NATIONAL ASSOCIATION AS TRUSTEE (Filed With SEC on November 2, 2016)

AMENDMENT NO. 1 TO THE LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT (Filed With SEC on August 9, 2016)

LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN THERAVANCE BIOPHARMA IRELAND LIMITED AND MILLENNIUM PHARMACEUTICALS, INC. DATED JUNE 8, 2016 (Filed With SEC on August 9, 2016)

THERAVANCE BIOPHARMA, INC. ORDINARY SHARE PURCHASE AGREEMENT March 14, 2016 (Filed With SEC on May 10, 2016)

THERAVANCE BIOPHARMA, INC. PERFORMANCE INCENTIVE PLAN PURPOSE (Filed With SEC on May 6, 2016)

THERAVANCE BIOPHARMA, INC. (a Cayman Islands exempted company) 4,765,000 Ordinary Shares UNDERWRITING AGREEMENT (Filed With SEC on May 2, 2016)

THERAVANCE BIOPHARMA, INC. 2013 EQUITY INCENTIVE PLAN NOTICE OF OPTION GRANT (Filed With SEC on March 11, 2016)

ACKNOWLEDGEMENT (Filed With SEC on March 11, 2016)

Theravance Biopharma, Inc. 2013 Equity Incentive Plan (the Plan) Irish Addendum (Filed With SEC on March 11, 2016)

Theravance Biopharma, Inc. 2014 New Employee Equity Incentive Plan (the Plan) Irish Addendum (Filed With SEC on March 11, 2016)

Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan (the Plan) UK Addendum (Filed With SEC on March 11, 2016)

FIRST AMENDMENT TO RIGHTS AGREEMENT (Filed With SEC on November 10, 2015)

Theravance Biopharma, Inc. (79) | Uncategorized (59)